UK Healthcare Gazette: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on UK Healthcare Gazette.

Press releases published on March 6, 2026

Unique Total Weight Management Model Targets Root Causes of Obesity for Sustainable Transformation
Why Video Marketing Continues to Dominate in 2026 — And How Video Plus Print Is Changing the Game
Biopharmaceutical Lab Equipment Market 2026: Technology Providers Accelerating Research Capabilities
New Global Women’s Health Programme Launches to Support Female Ultra-Trail Athletes: The Ultra Sports Health Lab
Pharmaceutical Safety Assessment Market 2026: Compliance and Risk Evaluation Trends
Real-Time CGM Patch Market 2026: Rising Demand for Continuous Glucose Monitoring Drives Innovation
Refurbished Laboratory Equipment Market 2026: Budget-Conscious Labs Turning to High-Quality Reconditioned Solutions
Drug Repositioning Service Market 2026: Companies Unlocking New Therapeutic Potential
PitPat Launches March Pisces Cycling Online Event to Energize Global Fitness Through Digital Competition
SourceFuse Announces Partnership with Databricks to Accelerate Global Data & AI Transformation
Business Reporter: It’s time for boards to embrace proactive AI governance
ProcellaRX Launches Ascend: Decision Quality. Trusted Partners. One Ecosystem
Sample Processing System Market 2026: Smarter Automation Streamlining Laboratory Efficiency
Health Coaching Market Expected to Grow at a 10.2% CAGR Between 2026 and 2030, Reaching $35.6 Billion in Revenue by 2030
LOXL2 Enzyme Discovery Offers New Hope for Jaw Arthritis
Protecting Women’s Progress in Tobacco Control
Comfy Sleepers Expands Butterfly Memory Foam Pillow Availability to the United States and United Kingdom
Medical Tubing Market Growth to Register 8.0% CAGR During 2026–2033 | Persistence Market Research
Transforming Healthcare Ltd Founder Dr. Pietro Emanuele Garbelli Wins BREW Readers' Book of the Month for 'The Doctor's Future'
Tangram Therapeutics gibt Dosierung des ersten Studienteilnehmers in der Phase-I/II-Studie RESTORE-MASH zu TGM-312 bekannt, einem in der Entwicklungsphase befindlichen RNAi-Therapeutikum

Share this page:

Sign up for:

UK Healthcare Gazette

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.